JP2018522062A - 腫瘍バイオマーカー及びその使用 - Google Patents

腫瘍バイオマーカー及びその使用 Download PDF

Info

Publication number
JP2018522062A
JP2018522062A JP2018513736A JP2018513736A JP2018522062A JP 2018522062 A JP2018522062 A JP 2018522062A JP 2018513736 A JP2018513736 A JP 2018513736A JP 2018513736 A JP2018513736 A JP 2018513736A JP 2018522062 A JP2018522062 A JP 2018522062A
Authority
JP
Japan
Prior art keywords
methylpyridin
amine
methyl
benzyl
naphthyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018513736A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018522062A5 (enExample
Inventor
チン、シャオリ
アン、ソンヅウ
フアン、タオ
Original Assignee
キュアジェニックス コーポレーション
キュアジェニックス コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キュアジェニックス コーポレーション, キュアジェニックス コーポレーション filed Critical キュアジェニックス コーポレーション
Publication of JP2018522062A publication Critical patent/JP2018522062A/ja
Publication of JP2018522062A5 publication Critical patent/JP2018522062A5/ja
Priority to JP2021089708A priority Critical patent/JP2021130694A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2018513736A 2015-05-26 2016-05-26 腫瘍バイオマーカー及びその使用 Pending JP2018522062A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021089708A JP2021130694A (ja) 2015-05-26 2021-05-28 腫瘍バイオマーカー及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562166305P 2015-05-26 2015-05-26
US62/166,305 2015-05-26
PCT/US2016/034245 WO2016191525A1 (en) 2015-05-26 2016-05-26 Tumor biomarkers and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021089708A Division JP2021130694A (ja) 2015-05-26 2021-05-28 腫瘍バイオマーカー及びその使用

Publications (2)

Publication Number Publication Date
JP2018522062A true JP2018522062A (ja) 2018-08-09
JP2018522062A5 JP2018522062A5 (enExample) 2019-04-18

Family

ID=57394192

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018513736A Pending JP2018522062A (ja) 2015-05-26 2016-05-26 腫瘍バイオマーカー及びその使用
JP2021089708A Pending JP2021130694A (ja) 2015-05-26 2021-05-28 腫瘍バイオマーカー及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021089708A Pending JP2021130694A (ja) 2015-05-26 2021-05-28 腫瘍バイオマーカー及びその使用

Country Status (9)

Country Link
US (2) US20180112273A1 (enExample)
EP (1) EP3302479A4 (enExample)
JP (2) JP2018522062A (enExample)
KR (1) KR20180010198A (enExample)
CN (1) CN107708699A (enExample)
AU (1) AU2016267142B2 (enExample)
CA (1) CA2985813A1 (enExample)
HK (1) HK1251171A1 (enExample)
WO (1) WO2016191525A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2905830C (en) 2013-03-12 2022-01-18 Curegenix Inc. Quinazoline and naphthyridine derivatives useful in the treatment of cancer
CN109415342A (zh) * 2016-06-22 2019-03-01 诺华股份有限公司 用于治疗纤维化的wnt抑制剂
EP3559264A4 (en) * 2016-12-21 2020-08-12 Agency for Science, Technology and Research MALIGNANT DISORDER IDENTIFICATION KIT AND ITS USES
CN107441045B (zh) 2017-07-21 2018-10-19 广州源生医药科技有限公司 用于递送Wnt信号通路抑制剂的脂质体制剂及其制备方法
CN108685923A (zh) * 2018-06-07 2018-10-23 广州源生医药科技有限公司 Wnt信号通路抑制剂在治疗LGR5阳性癌症中的应用
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013533879A (ja) * 2010-06-29 2013-08-29 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｗｎｔシグナル伝達経路調節のための組成物および方法
JP2014129381A (ja) * 2009-03-02 2014-07-10 Irm Llc Ｗｎｔシグナル伝達調節剤として使用するための、ｎ−（ヘテロ）アリール，２−（ヘテロ）アリール置換アセトアミド類
WO2014165232A1 (en) * 2013-03-12 2014-10-09 Curegenix, Inc. Compounds for treatment of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102558173B (zh) * 2010-12-31 2015-05-20 广州源生医药科技有限公司 抑制wnt信号传导的化合物、组合物及其应用
EP2812350B1 (en) * 2012-02-11 2019-04-03 F.Hoffmann-La Roche Ag R-spondin translocations and methods using the same
RU2017120287A (ru) * 2012-02-28 2018-11-15 АйАрЭм ЭлЭлСи ОТБОР БОЛЬНЫХ РАКОМ ДЛЯ ВВЕДЕНИЯ ИНГИБИТОРОВ СИГНАЛЬНОГО ПУТИ Wnt НА ОСНОВАНИИ СТАТУСА МУТАЦИИ RNF43
BR112016008477A2 (pt) * 2013-10-18 2017-10-03 Genentech Inc Corpos, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica e usos do anticorpo

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014129381A (ja) * 2009-03-02 2014-07-10 Irm Llc Ｗｎｔシグナル伝達調節剤として使用するための、ｎ−（ヘテロ）アリール，２−（ヘテロ）アリール置換アセトアミド類
JP2013533879A (ja) * 2010-06-29 2013-08-29 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｗｎｔシグナル伝達経路調節のための組成物および方法
WO2014165232A1 (en) * 2013-03-12 2014-10-09 Curegenix, Inc. Compounds for treatment of cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PNAS, vol. 110, no. 50, JPN6020011587, 2013, pages 20224 - 20229, ISSN: 0004575123 *

Also Published As

Publication number Publication date
KR20180010198A (ko) 2018-01-30
AU2016267142B2 (en) 2020-12-24
AU2016267142A1 (en) 2017-11-30
WO2016191525A1 (en) 2016-12-01
CA2985813A1 (en) 2016-12-01
US20210054466A1 (en) 2021-02-25
JP2021130694A (ja) 2021-09-09
HK1251171A1 (zh) 2019-01-25
CN107708699A (zh) 2018-02-16
EP3302479A4 (en) 2019-01-09
US20180112273A1 (en) 2018-04-26
EP3302479A1 (en) 2018-04-11

Similar Documents

Publication Publication Date Title
US10660889B2 (en) Compounds for treatment of cancer
US20210054466A1 (en) Tumor biomarkers and use thereof
US12441707B2 (en) Indazole compounds
JP7783436B2 (ja) Ｐａｒｇ阻害剤としてのピペラジン置換インダゾール化合物
ES2585352T3 (es) Compuestos bicíclicos heterocíclicos como inhibidores de la proteína tirosina quinasa
US8003662B2 (en) Heterobicyclic thiophene compounds and methods of use
US20110130406A1 (en) Pyrazolo-pyridines as tyrosine kinase inhibitors
JP6898919B2 (ja) 新規化合物
CN116406271A (zh) 双环类化合物
KR20080027775A (ko) 피롤(２,３-ｂ)피리딘 유도체 단백질 키나제 억제제
US10463653B2 (en) Use of ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors
EP3066099B1 (en) Pyrido[2,3-d]pyrimidin-4-one compounds as tankyrase inhibitors
CN110546145B (zh) 一种氮杂芳基衍生物、其制备方法和在药学上的应用
EP4567038A1 (en) Novel prmt5 inhibitor and use thereof
CN116568671A (zh) 杂环Cullin-RING泛素连接酶化合物及其用途
JP2018512859A (ja) Ｔｔｋ阻害剤化学療法の為の予後バイオマーカー
CN108685923A (zh) Wnt信号通路抑制剂在治疗LGR5阳性癌症中的应用
HK1161529A1 (en) Pyrazolopyrimidine jak inhibitor compounds and methods
HK1161529B (en) Pyrazolopyrimidine jak inhibitor compounds and methods

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190308

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190308

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200331

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200629

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200828

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200924

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210528

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210528

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210528

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20210713

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210716

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210720

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20210827

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20210831

C609 Written withdrawal of request for trial/appeal

Free format text: JAPANESE INTERMEDIATE CODE: C609

Effective date: 20211125